title: Anti-CD20 (rituximab) treatment for atopic eczema.
authors.forename: Anna
authors.initials: A
authors.lastname: Sedivá
authors.forename: Jana
authors.initials: J
authors.lastname: Kayserová
authors.forename: Eva
authors.initials: E
authors.lastname: Vernerová
authors.forename: Andrea
authors.initials: A
authors.lastname: Poloucková
authors.forename: Stepánka
authors.initials: S
authors.lastname: Capková
authors.forename: Radek
authors.initials: R
authors.lastname: Spísek
authors.forename: Jirina
authors.initials: J
authors.lastname: Bartůnková
mesh_terms: D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000187:drug effects; D003713:Dendritic Cells / Q000187:drug effects; D003876:Dermatitis, Atopic / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D004804:Eosinophils / Q000187:drug effects; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood / Q000187:drug effects; D010950:Plasma Cells / Q000187:drug effects; D000069283:Rituximab; D013601:T-Lymphocytes / Q000187:drug effects
chemical_list: D018926:Anti-Allergic Agents; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D007073:Immunoglobulin E; D000069283:Rituximab